212Pb-ADVC001 is an Alpha-emitting PSMA targeting radiolabeled molecule developed in Australia for patients with PSMA-positive mCRPC who have not had prior exposure to 177Lu-PSMA based radioligand therapies. A Phase I/II clinical trial has been initiated early 2023.
Target/Mechanism: PSMA
Carrier/Ligand: Peptide
Radiation Type: Alpha particle (α)